Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord blood-derived regulatory T cells
- Development stage
- Phase 2
- Lead developer
- Masonic Cancer Center
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
An investigational cell therapy consisting of ex vivo expanded umbilical cord blood (UCB)-derived regulatory T cells (Tregs) developed by the Masonic Cancer Center at the University of Minnesota. The therapy is specifically designed for the prevention of acute graft-versus-host disease (aGVHD) in adult patients undergoing double umbilical cord blood transplantation for hematologic malignancies. The active component consists of CD4+CD25+FoxP3+ regulatory T cells that are enriched from cryopreserved UCB and expanded using either anti-CD3/anti-CD28 antibody-coated beads and recombinant human interleukin-2 (IL-2) or K562 cells modified to express CD64 and CD86 (KT64/86). These Tregs function by suppressing the expansion and activation of CD8+ effector T cells in GVHD target organs, thereby reducing the incidence of grade II-IV acute GVHD without compromising the graft-versus-leukemia effect.
- Other names
- UCB-TregsCD4+CD25+FoxP3+ regulatory T cellsT regulatory cellsTregsex vivo expanded UCB-derived Tregs
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on umbilical cord blood-derived regulatory T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord blood-derived regulatory T cells.